Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Monday, August 12, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

-- New potential gastrointestinal and lung cancer therapies from Boehringer Ingelheim's innovative oncology pipeline will be combined with the patient-driven drug-development capabilities at MD Anderson

Boehringer Ingelheim



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store